NASDAQ$YMAB
Y-mAbs Therapeutics Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Y-mAbs Therapeutics reported Q1 2025 revenue of $20.9M, a net loss of $5.2M, diluted EPS of $-0.12.
For Q1 2025, Y-mAbs Therapeutics reported Revenue was $20.9M, net loss was $5.2M, diluted EPS was $-0.12. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Revenue $20.9M for Q1 2025.
- Net loss $5.2M.
- Diluted EPS $-0.12.
Headline financials
Revenue & EPS history
Y-mAbs · Revenue · Quarterly
$20.9M
Forward guidance
Biotech and specialty pharma outlook emphasizes pipeline milestones, label expansion, and collaboration funding.
Tailwinds
- Product or collaboration revenue supports near-term cash flows.
- Clinical and regulatory progress on lead programs.
Headwinds
- Operating losses and R&D spend remain elevated.
- Regulatory and competitive risks in oncology and specialty care.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports · overlaid with Q1 2025
+2.2%
Avg return
Earnings day
-4.2%
Avg return
5 days after
-5.4%
Avg return
30 days after
36%
10 / 28 earnings
Positive
+54.6%
Q4 2022
Best reaction
-21.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.0% | +0.0% | +0.8% | |
| Q1 2025 | -11.4% | +0.2% | +14.0% | |
| Q4 2024 | -4.4% | -0.4% | -9.9% | |
| Q3 2024 | -4.4% | -15.2% | -32.3% | |
| Q2 2024 | -3.5% | +9.4% | +18.4% | |
| Q1 2024 | -21.1% | -25.4% | -28.7% | |
| Q4 2023 | +14.5% | +2.0% | -0.2% | |
| Q3 2023 | +6.1% | — | — | |
| Q2 2023 | -5.0% | — | — | |
| Q1 2023 | +33.6% | — | — | |
| Q4 2022 | +54.6% | — | — | |
| Q3 2022 | +15.4% | — | — | |
| Q2 2022 | -5.6% | — | — | |
| Q1 2022 | +13.2% | — | — | |
| Q4 2021 | +12.9% | — | — | |
| Q3 2021 | -19.7% | — | — | |
| Q2 2021 | -17.8% | — | — | |
| Q1 2021 | +20.8% | — | — | |
| Q4 2020 | -3.6% | — | — | |
| Q3 2020 | -3.0% | — | — | |
| Q2 2020 | -1.6% | — | — | |
| Q1 2020 | +14.4% | — | — | |
| Q4 2019 | -8.7% | — | — | |
| Q3 2019 | -1.6% | — | — | |
| Q2 2019 | +2.4% | — | — | |
| Q1 2019 | -9.9% | — | — | |
| Q4 2018 | -4.4% | — | — | |
| Q3 2018 | -1.1% | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro